Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation

被引:105
作者
Hsiau, Margaret
Fernandez, Hilda E. [1 ]
Gjertson, David [2 ]
Ettenger, Robert B.
Tsai, Eileen W.
机构
[1] Univ Calif Los Angeles, Div Pediat Nephrol, Mattel Childrens Hosp, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA
关键词
Pediatric kidney transplantation; Tacrolimus; Mycophenolate mofetil; Immunosuppressant adherence; Trough level; Variability; RECIPIENTS; CHILDREN; ADHERENCE; OUTCOMES; THERAPY;
D O I
10.1097/TP.0b013e31822dc34f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Background. Acute rejection associated with medication nonadherence is a major cause of allograft loss in pediatric kidney transplant patients. There is currently no reliable method to detect medication nonadherence and prevent allograft rejection. Methods. In 46 pediatric patients who underwent renal transplantation between 2002 and 2003, the variation of serum drug levels was studied as a potential objective tool to monitor medication nonadherence. Tacrolimus (TAC) and mycophenolic acid (MPA) trough levels were measured from 1 to 12 months posttransplant, and standard deviation (SD) and percent coefficient of variation (CV%) were calculated. Because SD increased as mean trough levels rose, CV% (CV% = SD/mean multiplied by 100%) was used to eliminate this confounding effect. Results. Ten of 46 patients had biopsy-proven rejection. The median TAC CV% was 53.4% in patients with biopsyproven rejection, which was significantly higher than 30% in those without rejection (P = 0.005). Median MPA CV% was 51.9% in patients without rejection and 45.1% in patients with rejection (P = NS). High TAC CV% correlated with increased risk for rejection, whereas MPA CV% did not. Conclusion. The TAC CV% seems to be a useful and superior marker, compared with SD alone, for assessing medication nonadherence and the possibility of allograft rejection in pediatric renal transplantation.
引用
收藏
页码:918 / 922
页数:5
相关论文
共 14 条
[1]
Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[2]
Cecka J M, 1997, Pediatr Transplant, V1, P55
[3]
Immunosuppressant Therapy Adherence and Graft Failure Among Pediatric Renal Transplant Recipients [J].
Chisholm-Burns, M. A. ;
Spivey, C. A. ;
Rehfeld, R. ;
Zawaideh, M. ;
Roe, D. J. ;
Gruessner, R. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (11) :2497-2504
[4]
De Geest S, 1998, J HEART LUNG TRANSPL, V17, P854
[5]
IMPROVED CADAVERIC RENAL-TRANSPLANT OUTCOME IN CHILDREN [J].
ETTENGER, RB ;
ROSENTHAL, JT ;
MARIK, JL ;
MALEKZADEH, M ;
FORSYTHE, SB ;
KAMIL, ES ;
SALUSKY, IB ;
FINE, RN .
PEDIATRIC NEPHROLOGY, 1991, 5 (01) :137-142
[6]
Feldman HI, 1999, PHARMACOEPIDEM DR S, V8, P1
[7]
GERSON AC, PAS ANN M 2007 TOR C
[8]
Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children [J].
Pollock-BarZiv, Stacey M. ;
Finkelstein, Yaron ;
Manlhiot, Cedric ;
Dipchand, Anne I. ;
Hebert, Diane ;
Ng, Vicky L. ;
Solomon, Melinda ;
McCrindle, Brian W. ;
Grant, David .
PEDIATRIC TRANSPLANTATION, 2010, 14 (08) :968-975
[9]
Medication non-adherence in the adolescent renal transplant recipient: A clinician's viewpoint [J].
Rianthavorn, P ;
Ettenger, RB .
PEDIATRIC TRANSPLANTATION, 2005, 9 (03) :398-407
[10]
SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259